Quality of life from cytoreductive surgery in advanced ovarian cancer: Investigating the association between disease burden and surgical complexity in the international, prospective, SOCQER-2 cohort study

Sundar, S; Cummins, C; Kumar, S; Long, J; Arora, V; Balega, J; Broadhead, T; Duncan, T; Edmondson, R; Fotopoulou, C; Glasspool, R; Kolomainen, D; Leeson, S; Manchanda, R; McNally, O; Morrison, J; Mukhopadhyay, A; Paul, J; Tidy, J; Wood, N

Author(s): Sundar, S; Cummins, C; Kumar, S; Long, J; Arora, V; Balega, J; Broadhead, T; Duncan, T; Edmondson, R; Fotopoulou, C; Glasspool, R; Kolomainen, D; Leeson, S; Manchanda, R; McNally, O; Morrison, J; Mukhopadhyay, A; Paul, J; Tidy, J; Wood, N;
Details: Publication Year 2022-06,Volume 129,Issue #7,Page 1122-1132
Journal Title: BJOG
Publication Type: Research article
Abstract: OBJECTIVE: To investigate quality of life (QoL) and association with surgical complexity and disease burden after surgical resection for advanced ovarian cancer in centres with variation in surgical approach. DESIGN: Prospective multicentre observational study. SETTING: Gynaecological cancer surgery centres in the UK, Kolkata, India, and Melbourne, Australia. SAMPLE: Patients undergoing surgical resection (with low, intermediate or high surgical complexity score, SCS) for late-stage ovarian cancer. MAIN OUTCOME MEASURES: Primary: change in global score on the European Organisation for Research and Treatment of Cancer (EORTC) core quality-of-life questionnaire (QLQ-C30). Secondary: EORTC ovarian cancer module (OV28), progression-free survival. RESULTS: Patients' preoperative disease burden and SCS varied between centres, confirming differences in surgical ethos. QoL response rates were 90% up to 18 months. Mean change from the pre-surgical baseline in the EORTC QLQ-C30 was 3.4 (SD 1.8, n = 88) in the low, 4.0 (SD 2.1, n = 55) in the intermediate and 4.3 (SD 2.1, n = 52) in the high-SCS group after 6 weeks (p = 0.048), and 4.3 (SD 2.1, n = 51), 5.1 (SD 2.2, n = 41) and 5.1 (SD 2.2, n = 35), respectively, after 12 months (p = 0.133). In a repeated-measures model, there were no clinically or statistically meaningful differences in EORTC QLQ-C30 global scores between the three SCS groups (p = 0.840), but there was a small statistically significant improvement in all groups over time (p < 0.001). The high-SCS group experienced small to moderate decreases in physical (p = 0.004), role (p = 0.016) and emotional (p = 0.001) function at 6 weeks post-surgery, which resolved by 6-12 months. CONCLUSIONS: The global QoL of patients undergoing low-, intermediate- and high-SCS surgery improved at 12 months after surgery and was no worse in patients undergoing extensive surgery. TWEETABLE ABSTRACT: Compared with surgery of lower complexity, extensive surgery does not result in poorer quality of life in patients with advanced ovarian cancer.
Publisher: Wiley
Keywords: Carcinoma, Ovarian Epithelial/surgery; Cohort Studies; Cost of Illness; Cytoreduction Surgical Procedures; Female; Humans; *Ovarian Neoplasms/surgery; Prospective Studies; *Quality of Life; Surveys and Questionnaires; extensive surgery; ovarian cancer; quality of life; ultraradical surgery
Department(s): Medical Oncology
PubMed ID: 34865316
Publisher's Version: https://doi.org/10.1111/1471-0528.17041
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2025-04-11 03:02:51

Last Modified: 2025-04-11 03:05:16